Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
Royalty Pharma (RPRX) will report its fourth-quarter and full-year 2021 financial results on February 15, 2022, before market opening. The company will host a conference call at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, founded in 1996, is a major player in biopharmaceutical royalties, partnering with various organizations to fund innovation. Its portfolio includes royalties on over 40 commercial products from leading pharmaceutical companies, showcasing its extensive involvement in the sector.
ProKidney, a clinical-stage cellular therapeutics company, has initiated a business combination with Social Capital Suvretta Holdings Corp. III (DNAC). This partnership aims to accelerate the development of REACT®, a first-of-its-kind autologous cell therapy targeting chronic kidney disease (CKD), which has received RMAT designation. The deal values the combined entity at $2.64 billion and is projected to provide $825 million in gross cash proceeds to support REACT®'s Phase 3 clinical trials and manufacturing efforts. The patient population for REACT® exceeds 75 million across the U.S. and the EU.
Royalty Pharma (RPRX) provides a business performance update, projecting 2021 Net cash from operating activities between $2,010 and $2,030 million and Adjusted Cash Receipts at $2,110 to $2,130 million, an 18% increase year-over-year. The company added 20 therapies to its portfolio, with 9 expected to be blockbusters. Recent transactions valued at $5.5 billion aim to boost Adjusted Cash Receipts by over $750 million in 2025. The CEO highlights strong capital deployment and innovation funding as key growth drivers.
Royalty Pharma has announced its investment in Cytokinetics, providing up to $300 million for the commercialization of omecamtiv mecarbil and development of aficamten. The funds will be distributed in five tranches, with an initial $50 million upon closing. Additionally, Royalty Pharma has acquired a 4.5% royalty on aficamten sales up to $1 billion. Cytokinetics aims to utilize this funding to secure a cash runway for at least two years, enhancing its position in the cardiovascular market.
Royalty Pharma plc (Nasdaq: RPRX) announced a 12% increase in its quarterly dividend, now set at $0.19 per Class A share for Q1 2022. The dividend will be paid on March 15, 2022, to shareholders of record as of February 18, 2022. This reflects Royalty Pharma's ongoing commitment to returning value to its shareholders while leveraging its extensive portfolio of biopharmaceutical royalties.
Royalty Pharma (Nasdaq: RPRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 a.m. ET. The conference offers a platform for the company to showcase its position as the largest buyer of biopharmaceutical royalties.
The webcast will be available on Royalty Pharma's Events page and archived for at least thirty days. Established in 1996, the company collaborates to fund innovation and holds royalties on over 40 leading therapies.
Royalty Pharma plc (Nasdaq: RPRX) will participate in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 9:40 a.m. ET. The event will include a fireside chat accessible via the company’s Events page, with the webcast archived for at least thirty days. Founded in 1996, Royalty Pharma is a leader in funding biopharmaceutical innovation, holding royalties on approximately 40 commercial products from major pharmaceutical companies, facilitating advancements in healthcare.
On November 22, 2021, Royalty Pharma (RPRX) and OMERS Capital Markets announced $350 million funding for BioCryst Pharmaceuticals (BCRX). This capital will support the advancement of BCX9930, an oral Factor D inhibitor, and further investment in the global launch of ORLADEYO® (berotralstat), which targets hereditary angioedema (HAE). Royalty Pharma's agreement includes royalties on sales and a $50 million equity investment in BioCryst at $13.00 per share. The funds will accelerate pivotal trials and regulatory filings for BCX9930, reinforcing BioCryst's growth strategy.
Royalty Pharma (RPRX) reported strong Q3 2021 results, with net cash from operating activities at $470 million and adjusted cash receipts rising 24% to $587 million. The company announced $2.8 billion in transactions for 2021, comprising $2.1 billion in upfront payments. Q3 2021 total income increased 9% to $586 million. The company raised its 2021 guidance for adjusted cash receipts to between $2,110 million and $2,130 million, representing 17%-18% growth year-on-year. Notable developments include positive Phase 3 results for PT027 in asthma and FDA designation of gantenerumab as a Breakthrough Therapy for Alzheimer’s.
Royalty Pharma (RPRX) will release its Q3 2021 financial results on November 10, 2021, before U.S. markets open. The announcement includes a conference call at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, a leader in biopharmaceutical royalties, partners with innovators to fund clinical trials and acquire royalties from top therapies, including Imbruvica and Xtandi. The company has royalties on over 45 commercial products and nine developmental candidates, positioning it as a significant player in the biopharmaceutical sector.
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
